HTFL vs RXRX vs SDGR vs NVDA

For growth investors, NVIDIA Corporation (NVDA) is the stronger pick with 65.

5% revenue growth year-over-year, versus 23. 3% for Schrödinger, Inc. (SDGR). NVIDIA Corporation (NVDA) offers the better valuation at 45. 1x trailing P/E (26. 7x forward), making it the more compelling value choice. Analysts rate Heartflow, Inc. Common Stock (HTFL) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, NVIDIA Corporation (NVDA) delivered a total return of +1506%, compared to -85.

8% for Recursion Pharmaceuticals, Inc. (RXRX). Over 10 years, the gap is even starker: NVDA returned +247. 6% versus RXRX's -82. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Schrödinger, Inc.

(SDGR) is the lower-risk stock at 1. 65β versus Recursion Pharmaceuticals, Inc. 's 2. 99β — meaning RXRX is approximately 81% more volatile than SDGR relative to the S&P 500. On balance sheet safety, Recursion Pharmaceuticals, Inc. (RXRX) carries a lower debt/equity ratio of 7% versus 30% for Schrödinger, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), NVIDIA Corporation (NVDA) is pulling ahead at 65.

5% versus 23. 3% for Schrödinger, Inc. (SDGR). On earnings-per-share growth, the picture is similar: NVIDIA Corporation grew EPS 66. 7% year-over-year, compared to 8. 1% for Heartflow, Inc. Common Stock. Over a 3-year CAGR, NVDA leads at 100. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

NVIDIA Corporation (NVDA) is the more profitable company, earning 55.

6% net margin versus -863. 4% for Recursion Pharmaceuticals, Inc. — meaning it keeps 55. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVDA leads at 60. 4% versus -867. 9% for RXRX. At the gross margin level — before operating expenses — HTFL leads at 76. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for RXRX: 249.

2% to $11. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, NVIDIA Corporation (NVDA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+247.

6% 10Y return). Recursion Pharmaceuticals, Inc. (RXRX) carries a higher beta of 2. 99 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NVDA: +247. 6%, RXRX: -82. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (HTFL (Healthcare) and RXRX (Healthcare) and SDGR (Healthcare) and NVDA (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.